$250 millionHealthcare
Multiples-backed BDR Pharma buys control of Acme's oral solids unit
Oral solid formulations business of Acme Formulation, bought from existing investors including PAG, with an expected value of about $250 million.
Multiples Private Equity
1 deals covered
1 add-on
Most recent deal Sunday, November 8, 2026.
Platforms: BDR Pharmaceuticals International (1 add-on)